Vonoprazan: First Global Approval

Mo1053 A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis

(2015) Tsutomu Chiba et al.   GASTROENTEROLOGY

Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis

(2014) Eiji Umegaki et al.   GASTROENTEROLOGY

Tu1055 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Low-Dose Aspirin Therapy: Results of a Phase 3 Trial

(2014) Takashi Kawai et al.   GASTROENTEROLOGY

Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori

(2014) Kazunari Murakami et al.   GASTROENTEROLOGY

Tu1054 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy: Results of a Phase 3 Trial

(2014) Yuji Mizokami et al.   GASTROENTEROLOGY

Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis

(2014) Katsuhiko Iwakiri et al.   GASTROENTEROLOGY

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers

(2014) Hua-Jun Luo et al.   PLoS One

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

(2012) Yasuyoshi Arikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS